Monoamine Oxidase Inhibitors

"Monoamine Oxidase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p414)

Descriptor ID	D008996
MeSH Number(s)	D27.505.519.389.616
Concept/Terms	Monoamine Oxidase Inhibitors Monoamine Oxidase Inhibitors Inhibitors, Monoamine Oxidase Monoamine Oxidase Inhibitor Inhibitor, Monoamine Oxidase MAO Inhibitors Inhibitors, MAO RIMA (Reversible Inhibitor of Monoamine Oxidase A) RIMA (Reversible Inhibitor of Monoamine Oxidase A) Reversible Inhibitors of Monoamine Oxidase Reversible Inhibitors of Monoamine Oxidase Reversible Inhibitor of Monoamine Oxidase

Below are MeSH descriptors whose meaning is more general than "Monoamine Oxidase Inhibitors".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Enzyme Inhibitors [D27.505.519.389]
Monoamine Oxidase Inhibitors [D27.505.519.389.616]

Below are MeSH descriptors whose meaning is related to "Monoamine Oxidase Inhibitors".

Below are MeSH descriptors whose meaning is more specific than "Monoamine Oxidase Inhibitors".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Monoamine Oxidase Inhibitors" by people in this website by year, and whether "Monoamine Oxidase Inhibitors" was a major or minor topic of these publications.

Bar chart showing 16 publications over 11 distinct years, with a maximum of 3 publications in 2016

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	1	0	1
1996	1	0	1
1997	1	0	1
1998	0	2	2
2000	0	1	1
2001	0	1	1
2007	0	1	1
2015	1	1	2
2016	3	0	3
2017	2	0	2
2018	1	0	1

Below are the most recent publications written about "Monoamine Oxidase Inhibitors" by people in Profiles.

Kinslow CJ, Shapiro SD, Grunebaum MF, Miller EC. Acute hypertensive crisis and severe headache after concurrent use of armodafinil and tranylcypromine: Case report and review of the literature. J Neurol Sci. 2018 10 15; 393:1-3.

View in: PubMed
Larit F, Elokely KM, Chaurasiya ND, Benyahia S, Nael MA, León F, Abu-Darwish MS, Efferth T, Wang YH, Belouahem-Abed D, Benayache S, Tekwani BL, Cutler SJ. Inhibition of human monoamine oxidase A and B by flavonoids isolated from two Algerian medicinal plants. Phytomedicine. 2018 Feb 01; 40:27-36.

View in: PubMed
Hauser RA, Li R, Pérez A, Ren X, Weintraub D, Elm J, Goudreau JL, Morgan JC, Fang JY, Aminoff MJ, Christine CW, Dhall R, Umeh CC, Boyd JT, Stover N, Leehey M, Zweig RM, Nicholas AP, Bodis-Wollner I, Willis A, Kieburtz K, Tilley BC. Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An Analysis of NET-PD LS1. J Parkinsons Dis. 2017; 7(1):117-127.

View in: PubMed
Chaurasiya ND, Gogineni V, Elokely KM, León F, Núñez MJ, Klein ML, Walker LA, Cutler SJ, Tekwani BL. Isolation of Acacetin from Calea urticifolia with Inhibitory Properties against Human Monoamine Oxidase-A and -B. J Nat Prod. 2016 10 28; 79(10):2538-2544.

View in: PubMed
Weintraub D, Hauser RA, Elm JJ, Pagan F, Davis MD, Choudhry A. Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo-controlled trial. Mov Disord. 2016 05; 31(5):709-14.

View in: PubMed
Smith TT, Rupprecht LE, Cwalina SN, Onimus MJ, Murphy SE, Donny EC, Sved AF. Effects of Monoamine Oxidase Inhibition on the Reinforcing Properties of Low-Dose Nicotine. Neuropsychopharmacology. 2016 08; 41(9):2335-43.

View in: PubMed
Ledreux A, Boger HA, Hinson VK, Cantwell K, Granholm AC. BDNF levels are increased by aminoindan and rasagiline in a double lesion model of Parkinson?s disease. Brain Res. 2016 Jan 15; 1631:34-45.

View in: PubMed
Smith TT, Schaff MB, Rupprecht LE, Schassburger RL, Buffalari DM, Murphy SE, Sved AF, Donny EC. Effects of MAO inhibition and a combination of minor alkaloids, ß-carbolines, and acetaldehyde on nicotine self-administration in adult male rats. Drug Alcohol Depend. 2015 Oct 01; 155:243-52.

View in: PubMed
Coatrieux C, Sanson M, Negre-Salvayre A, Parini A, Hannun Y, Itohara S, Salvayre R, Auge N. MAO-A-induced mitogenic signaling is mediated by reactive oxygen species, MMP-2, and the sphingolipid pathway. Free Radic Biol Med. 2007 Jul 01; 43(1):80-9.

View in: PubMed
Ballenger JC. Overview of different pharmacotherapies for attaining remission in generalized anxiety disorder. J Clin Psychiatry. 2001; 62 Suppl 19:11-9.

View in: PubMed

People

Explore

Similar Concepts

Top Journals